Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities
The DOI matches its Crossref record; 75 of the 77 references it cites were found in a registry or an index.
Abstract
Heterozygous mutations in catalytic arginine residues of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) are common in glioma, acute myeloid leukemia, chondrosarcoma, cholangiocarcinoma, and angioimmunoblastic T-cell lymphoma. The mutant enzymes acquire a neomorphic activity that converts α-ketoglutarate (α-KG) to D-2-hydroxyglutarate (D2HG), a rare metabolite. In cells and tissues expressing mutant IDH, D2HG concentrations are highly elevated. D2HG may act as an “oncometabolite” by inhibiting a class of α-KG–dependent enzymes involved in epigenetic regulation, collagen synthesis, and cell signaling. Knock-in mouse models of IDH1 mutations have shed light on these mechanisms and will provide valuable animal models for further investigation. Significance: Mutations in IDH1 and IDH2 promote the development of a number of malignancies. These active site mutations cause a gain-of-function leading to the accumulation of the rare metabolite D2HG. Mouse models of these mutations should provide insights into the mechanisms driving tumorigenesis and facilitate evaluation of new treatments. Cancer Discov; 3(7); 730–41. ©2013 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [7]
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [7]
In the citing paper
“Insulator dysfunction may also be accompanied by promoter silencing events28,29, and by alterations to other pathways affected by 2-HG7,30.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [7]
In the citing paper
“This can occur through multiple distinct mechanisms, including recurrent gain- or loss-of function mutations in enhancer of zeste 2 (EZH2), the primary methyltransferase responsible for this histone modification 99 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [99]
In the citing paper
“EZH2 catalyses mono-, di- and tri-methylation of H3K27, which is linked to transcriptional silencing 99 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [99]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Self-citationCancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., et al. (2012) · Nature · doi:10.1038/nature10860 · Cited by 1,985
Cited by
Items 201–300 of 478
Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth
Li, L., Hu, X., Eid, J. E., Rosenberg, A. E., Wilky, B. A., Ban, Y. J., Sun, X., Galoian, K. A., DeSalvo, J., Yue, J., et al. (2020) · Cancers · doi:10.3390/cancers12010141 · Cited by 27
“IDH1 is localized in the cytoplasm and peroxisomes whereas IDH2 and IDH3 are mitochondrial [4].”
Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells
Chen, D., Xia, S., Zhang, R., Li, Y., Famulare, C. A., Fan, H., Wu, R., Wang, M., Zhu, A. C., Elf, S., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.06.027 · Cited by 26
The metabolic addiction of cancer stem cells
Sahoo, O. S., Pethusamy, K., Srivastava, T. P., Talukdar, J., Alqahtani, M. S., Abbas, M. A. E., Dhar, R., & Karmakar, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.955892 · Cited by 26
IDH1 mutation detection by droplet digital PCR in glioma
Wang, J., Zhao, Y.-Y., Li, J.-F., Guo, C., Chen, F.-R., Su, H.-K., Zhao, H., Long, Y., Shao, J., To, S. S. T., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5630 · Cited by 30
“In addition to the important role in glioma, IDH mutations were found in myeloid neoplasia, peripheral T-cell lymphoma, chondrosarcoma, chonangiocarcinoma, prostate cancer, and other cancers [7, 8].”
BackgroundMohammad, N., Wong, D., Lum, A. M., Lin, J., Ho, J., Lee, C., & Yip, S. S. F. (2019) · Histopathology · doi:10.1111/his.14018 · Cited by 26
“This results in CpG island hypermethylation, and competitive inhibition of histone demethylases, causing altered histone modification.(9,12) Elevated 2HG levels have been reported in low‐grade cartilaginous neoplasms but not in DDCHS.”
BackgroundIsocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias
Testa, U., Castelli, G., & Pelosi, E. (2020) · Cancers · doi:10.3390/cancers12092427 · Cited by 29
“In spite of these similarities, important clinical differences between IDH-mutant and TET2-mutant hematopoietic disorders and differences in alterations at the level of DNA damage repair mechanisms suggest that the oncogenic mechanisms of these mutated enzymes may differ [89].”
BackgroundQuantification of 2-Hydroxyglutarate Enantiomers by Liquid Chromatography-mass Spectrometry
Oldham, W. M., & Loscalzo, J. (2016) · BIO-PROTOCOL · doi:10.21769/bioprotoc.1908 · Cited by 28
“More recently, investigators have shown that D2HG is produced by mutant isocitrate dehydrogenase enzymes associated with a variety of human malignancies, such as acute myeloid leukemia, glioblastoma multiforme, and cholangiocarcinoma (Cairns and Mak, 2013; Dang et al., 2009; Ward et al., 2010).”
BackgroundImpact of DNA methylation programming on normal and pre-leukemic hematopoiesis
Langstein, J., Milsom, M. D., & Lipka, D. B. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.09.008 · Cited by 26
“IDH1 is found in peroxisomes and in the cytoplasm whereas IDH2 is located in the mitochondrial matrix [163].”
BackgroundAzzi, G., Velez, M., & Mathias-Machado, M. C. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000092 · Cited by 25
“Selective compounds leading to mutant IDH1 inhibition have been developed showing potent activity with a significant decrease in 2-hydroxyglutarate levels in vitro in IDH1-mutated (R132H, R132C) glioblastoma and chondrosarcoma cell lines as well as in vivo in glioblastoma tumor xenograft [3,4].”
BackgroundHarnessing the power of sphingolipids: Prospects for acute myeloid leukemia
Ung, J., Tan, S., Fox, T. E., Shaw, J. J. P., Vass, L. R., Costa‐Pinheiro, P., Garrett-Bakelman, F. E., Keng, M. K., Sharma, A. K., Claxton, D. F., et al. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100950 · Cited by 25
IDH1-R132 changes vary according to NPM1 and other mutations status in AML
Falini, B., Spinelli, O., Meggendorfer, M., Martelli, M. P., Bigerna, B., Ascani, S., Stein, H., Rambaldi, A., & Haferlach, T. (2019) · Leukemia · doi:10.1038/s41375-018-0299-2 · Cited by 25
Yang, H., Yu, H., Liu, Y., Chen, T., Stern, A., Lo, S. J., & Chiu, D. T.-Y. (2019) · Journal of Molecular Medicine · doi:10.1007/s00109-018-01740-2 · Cited by 24
“IDH1/2 mutations have been found in glioma, glioblastoma, acute mye l og enou s l e uk em i a , c hond r o s a r c oma , a nd enchondroma [15, 16].”
BackgroundIlluminating the cross-talk between tumor metabolism and immunity in IDH-mutated cancers
Leca, J., Fortin, J., & Mak, T. W. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.11.013 · Cited by 25
Self-citationThe genetics of myelodysplastic syndromes and the opportunities for tailored treatments
Kontandreopoulou, C., Kalopisis, K., Viniou, N., & Diamantopoulos, P. T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.989483 · Cited by 24
The Roles of IDH1 in Tumor Metabolism and Immunity
Ni, Y., Shen, P., Wang, X. T., Liu, H., Luo, H., & Han, X. (2022) · Future Oncology · doi:10.2217/fon-2022-0583 · Cited by 24
Idh1 mutations contribute to the development of T-cell malignancies in genetically engineered mice
Hao, Z., Cairns, R. A., Inoue, S., Li, W. Y., Sheng, Y., Lemonnier, F., Wakeham, A. C., Snow, B. E., Dominguez‐Brauer, C., Ye, J., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525354113 · Cited by 23
“Although mutations in both genes result in gain of enzymatic function and production of 2HG, there are significant differences in the frequencies of IDH1 and IDH2 mutations in different diseases (1).”
BackgroundSelf-citationNovel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?
Stahl, M. F., Lu, B. Y., Kim, T. K., & Zeidan, A. M. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0503-8 · Cited by 22
Liu, X., Yamaguchi, K., Takane, K., Zhu, C., Hirata, M., Hikiba, Y., Maeda, S., Furukawa, Y., & Ikenoue, T. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257090 · Cited by 28
Taking a Bad Turn: Compromised DNA Damage Response in Leukemia
Nilles, N., & Fahrenkrog, B. (2017) · Cells · doi:10.3390/cells6020011 · Cited by 24
“In this context, changes in isocitrate dehydrogenase 1 and 2 (IDH1/2) and in the dioxygenase ten-eleven translocation 2 (TET2) (Figure 2D) are driver mutations in myeloid malignancies, but the underlying mechanisms remain rather obscure [122,123].”
BackgroundSignaling Transduction and Metabolomics
Puigserver, P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00007-x · Cited by 26
Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation
Huang, C., Iwagami, Y., Zou, J., Casulli, S., Lu, S., Nagaoka, K., Ji, C., Ogawa, K., Cao, K. Y., Gao, J., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.04.041 · Cited by 23
“It is of interest that clinical studies have demonstrated that CCAs with IDH1/2 mutations have a better prognosis than those with wildtype sequences [12, 13], indicating that 2-OGdependent dioxygenases could be important for CCA development and growth.”
BackgroundZhang, L., Qi, M., Feng, T., Hu, J., Wang, L., Li, X., Gao, W. Q., Liu, H., Jiao, M., Wu, Z., et al. (2018) · Neoplasia · doi:10.1016/j.neo.2017.12.001 · Cited by 22
“IDH1 mutations can cause alterations in cellular metabolism, histone modification, and DNA methylation [5].”
BackgroundMitochondrial Alterations in Prostate Cancer: Roles in Pathobiology and Racial Disparities
Vikramdeo, K. S., Sharma, A., Anand, S., Sudan, S. K., Singh, S., Singh, A. P., & Dasgupta, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054482 · Cited by 22
“Mutations in isocitrate dehydrogenase isoforms IDH1/2 were found in several cancers, including PCa [79].”
BackgroundGenetically Modeled Mice with Mutations in Mitochondrial Metabolic Enzymes for the Study of Cancer
Piruat, J. I., & Millán‐Uclés, Á. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00200 · Cited by 23
Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway
Addie, R. D., de Jong, Y., Alberti, G., Kruisselbrink, A. B., Que, I., Baelde, H. J., & Bovée, J. V. M. G. (2019) · Journal of bone oncology · doi:10.1016/j.jbo.2019.100222 · Cited by 20
Metabostemness in cancer: Linking metaboloepigenetics and mitophagy in remodeling cancer stem cells
Naik, P. P., Panigrahi, S., Parida, R., Praharaj, P. P., Bhol, C. S., Patil, S., Manjunath, N., Ghosh, D., Patra, S. K., & Bhutia, S. K. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10216-9 · Cited by 20
Vitamin C and D supplementation in acute myeloid leukemia
Mouchel, P., Bérard, E., Tavitian, S., Gadaud, N., Vergez, F., Rieu, J., Luquet, I., Sarry, A., Huguet, F., Largeaud, L., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010559 · Cited by 21
“9 AML with TET2 mutations displays an overlapping hypermethylation signature with IDH1/2 -mutated AML and mutual exclusivity between these 2 mutations is observed in patients with AML.”
BackgroundPediatric glioma histone H3.3 K27M/G34R mutations drive abnormalities in PML nuclear bodies
Voon, H. P. J., Hii, L. L., Garvie, A., Udugama, M., Krug, B., Russo, C., Chüeh, A. C., Daly, R. J., Morey, A., Bell, T. D. M., et al. (2023) · Genome biology · doi:10.1186/s13059-023-03122-5 · Cited by 20
“Interestingly, glial and myeloid malignancies are both also frequently mutated in IDH1 and IDH2 [65].”
BackgroundLuk, I. S. U., Bridgwater, C. M., Yu, A. Y. C., Boila, L. D., Yáñez-Bartolomé, M., Lampano, A., Hulahan, T. S., Boukhali, M., Kathiresan, M., Macarulla, T. M., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adj7685 · Cited by 23
“Hotspot mutations in the isocitrate binding domain of IDH are known to promote cancers in many cell lineages through gain- of-function enzymatic activity, which produces the oncometabolite R ( − )–2-hydroxyglutarate (2-HG) ( 7 ).”
BackgroundEke, I., Makinde, A. Y., Aryankalayil, M. J., Ahmed, M. M., & Coleman, C. N. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.041 · Cited by 20
“As the IDH mutation status is a strong predictor for patient outcome, non-invasive imaging of D-2-hydroxyglutarate with nuclear magnetic resonance spectroscopy could be used for risk stratification when genetic tumor profiling is not feasible [104,109–111].”
BackgroundInfluentialChitneni, S. K., Reitman, Z. J., Gooden, D. M., Yan, H., & Zalutsky, M. R. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.04.066 · Cited by 20
Kiesel, V. A., Sheeley, M. P., Hicks, E. M., Andolino, C. J., Donkin, S. S., Wendt, M. K., Hursting, S. D., & Teegarden, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.767479 · Cited by 20
Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma
Zabransky, D. J., Kartalia, E., Lee, J. W., Leatherman, J. M., Charmsaz, S., Young, S. E., Chhabra, Y., Franch‐Expósito, S., Kang, M., Maru, S. Y., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000001185 · Cited by 21
Functions for diverse metabolic activities in heterochromatin
Su, X. B., & Pillus, L. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518707113 · Cited by 22
“This point will be particularly important when developing therapies against the increasingly recognized IDH mutant-bearing tumors (63, 64), because strategies to balance or compensate for decreased α-ketoglutarate may cause negative secondary effects.”
BackgroundCancer knocks you out by fasting: Cachexia as a consequence of metabolic alterations in cancer
Cortellino, S., D’Angelo, M., Quintiliani, M., & Giordano, A. (2024) · Journal of Cellular Physiology · doi:10.1002/jcp.31417 · Cited by 20
“…promote inflammation via epigenetic reprogramming and genomic hypermethylation due to the production and accumulation of D2 ‐ HG and succinate oncometabo-lites, which inhibit α ‐ ketoglutarate ‐ dependent dioxygenases (TETs) and histone demethylases (KDM) (Cairns & Mak, 2013; Cascón et al., 2019).”
Fire and water: Tumor cell adaptation to metabolic conditions
Cairns, R. A., & Mak, T. W. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.04.029 · Cited by 18
Self-citationIDH1 mutation promotes lung cancer cell proliferation through methylation of Fibulin-5
Yan, B., Hu, Y., Ma, T., & Wang, Y. (2018) · Open Biology · doi:10.1098/rsob.180086 · Cited by 19
Association of TP53 Alteration with Tissue Specificity and Patient Outcome of IDH1-Mutant Glioma
Murnyák, B., & Huang, L. E. (2021) · Cells · doi:10.3390/cells10082116 · Cited by 22
“Although they were thought to be virtually exclusive in glioma [11,14], further mutational analyses revealed IDH1 and IDH2 mutations, as well as IDH2 Arg140 mutations, in various cancer types such as myeloid neoplasia, chondrosarcoma, cholangiocarcinoma, and prostate cancer [2,15].”
BackgroundCosta, C., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.011 · Cited by 18
“IDH1 and IDH2 mutations are well-established examples of neomorphic mutations in which the mutant enzymes catalyze a reaction not performed by the wild-type enzyme (Dang et al., 2009; Cairns and Mak, 2013).”
BackgroundWang, X., Inaoka, D. K., Shiba, T., Balogun, E. O., Allmann, S., Watanabe, Y., Boshart, M., Kita, K., & Harada, S. (2017) · Protein Expression and Purification · doi:10.1016/j.pep.2017.06.011 · Cited by 18
“IDH3 catalyzes the third-step reaction of the tricarboxylic citric aci d (TCA) cycle [11] and produces NADH to feed the respiratory chain through mitochondrial NA DH dehydrogenase complex (complex I)”
BackgroundWatts, J. M., Shaw, S. J., & Jonas, B. A. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01264-7 · Cited by 17
Cortes, J. E., Roboz, G. J., Baer, M. R., Jonas, B. A., Schiller, G. J., Yee, K. W. L., Ferrell, P. B., Yang, J., Wang, E. S., Blum, W. G., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01657-z · Cited by 17
“Furthermore, wild-type IDH1 catalyzes the conversion of isocitrate to α-KG and it has been shown that low levels of α-KG can block hemoglobin production and cause anemia linked to erythropoiesis disruption [8, 9].”
Regulators of carcinogenesis: Emerging roles beyond their primary functions
Jia, L., Zhang, R., Shen, L., & Yang, A. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.11.048 · Cited by 19
Structural Requirements of 2-Oxoglutaric Acid Analogues To Mimic Its Signaling Function
Liu, X., Wang, Y., Laurini, E., Posocco, P., Chen, H., Ziarelli, F., Janicki, A., Qu, F., Fermeglia, M., Pricl, S., et al. (2013) · Organic Letters · doi:10.1021/ol401914z · Cited by 17
Fang, B., Zhang, M., Ge, K., Xing, H. Z., & Ren, F. (2018) · Journal of Dairy Science · doi:10.3168/jds.2017-13731 · Cited by 18
“Taken together, this suggests that α-LA-OA increases the production of ROS though influencing energy metabolism, which may induce loss of the mitochondrial membrane potential and, as a consequence, activate apoptosis (Circu and Aw, 2010).”
BackgroundInfluentialKoseki, J., Colvin, H. S., Fukusumi, T., Nishida, N., Konno, M., Kawamoto, K., Tsunekuni, K., Matsui, H., Doki, Y., Mori, M., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2833 · Cited by 18
An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors
Verdura, S., Cuyàs, E., Lozano‐Sánchez, J., Bastidas-Velez, C., Llorach-Parés, L., Fernández‐Arroyo, S., Hernández‐Aguilera, A., Joven, J., Nonell‐Canals, A., Bosch‐Barrera, J., et al. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy159 · Cited by 19
Diagnosis and treatment of lymphomas in the era of epigenetics
Chebly, A., Chouery, É., Ropio, J., Kourié, H. R., Beylot-Barry, M., Merlio, J., Tomb, R. R., & Chevret, E. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100782 · Cited by 17
Another small molecule in the oncometabolite mix: L-2-Hydroxyglutarate in kidney cancer
Shim, E., & Sudarshan, S. (2015) · Oncoscience · doi:10.18632/oncoscience.165 · Cited by 17
“This chiral molecule is structurally similar to α-KG and is normally present at low levels in both its D-/L-enantiomers [5].”
BackgroundFujiwara, H., Tateishi, K., Kato, H., Nakatsuka, T., Yamamoto, K., Tanaka, Y., Ijichi, H., Takahara, N., Mizuno, S., Kogure, H., et al. (2018) · Cancer Science · doi:10.1111/cas.13784 · Cited by 17
“Isocitrate dehydrogenase (IDH) is the enzyme responsible for the conversion of isocitrate to α‐ketoglutarate (α‐KG) in the cytosol (IDH1) and mitochondria (IDH2).(11) When the mutation occurs in the catalytic site of the enzyme, a specific metabolite R(–)‐2‐hydroxyglutarate (2‐HG) is produced from α‐KG.”
BackgroundLi, Z., Zhao, W., He, B., Koh, T. S., Li, Y., Zeng, Y., Zhang, Z., Zhang, J., & Hou, Z. (2020) · Contrast Media & Molecular Imaging · doi:10.1155/2020/8843084 · Cited by 17
“Mutations in the IDH genes result in disruption of the enzyme’s normal catalytic activity and production of 2-hydroxyglutarate (2-HG), an oncometabolite, which leads to genetic and epigenetic dysregulation and subsequent tumorigenesis [49].”
BackgroundMenéndez, J. A. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150710150327 · Cited by 16
IDH1/2 Mutations in Cancer: Unifying Insights and Unlocking Therapeutic Potential for Chondrosarcoma
Deshmukh, S., Kelly, C. M., & Tinoco, G. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01115-3 · Cited by 16
Infratentorial Glioblastoma Metastasis to Bone
Ricard, J. A., Cramer, S. W., Charles, R., Tommee, C. G., Le, A., Bell, W. R., Chen, C. C., & Flanagan, M. E. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.07.142 · Cited by 15
Genetically Modified Cellular Therapies for Malignant Gliomas
Kilian, M., Bunse, T., Wick, W., Platten, M., & Bunse, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312810 · Cited by 16
Methyl Group Metabolism in Differentiation, Aging, and Cancer
Erichsen, L., Thimm, C., & Santourlidis, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158378 · Cited by 16
“D-2HG was found to inhibit the function of DNA and histone demethylases and was associated with altered epigenetic regulation, collagen synthesis, and cell signaling [54].”
BackgroundNew Insights in AML Biology From Genomic Analysis
Perry, A. M., & Attar, E. C. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.08.005 · Cited by 16
Lee, C. L., O'Kane, G. M., Mason, W. P., Zhang, W.-J., Spiliopoulou, P., Hansen, A. R., Grant, R. C., Knox, J. J., Stockley, T. L., Zadeh, G. M., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0460 · Cited by 15
“However, IDH1/2 mutations preferentially convert a KG to R-2-hydroxyglutarate (R2HG) (9, 10).”
BackgroundShifting the Gears of Metabolic Plasticity to Drive Cell State Transitions in Cancer
Wu, Z., Lee, Y. F., Yeo, X. H., Loo, S. Y., & Tam, W. L. (2021) · Cancers · doi:10.3390/cancers13061316 · Cited by 16
“Isocitrate dehydrogenase (IDH) is another TCA cycle enzyme that converts isocitrate to alpha-ketoglutarate, and IDH1/IDH2 mutations have been reported in a number of cancers including leukemia, melanomas, oligodendrogliomas, and astrocytomas [78].”
BackgroundThe epigenetics of brain tumors and its modulation during radiation: A review
Raviraj, R., Nagaraja, S. S., Selvakumar, I., Mohan, S., & Nagarajan, D. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117974 · Cited by 17
Marker, D. F., Agnihotri, S., Amankulor, N., MURDOCH, G. H., & Pearce, T. M. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab182 · Cited by 19
Shi, C., Wang, Y., Guo, J., Zhang, D., Zhang, Y., Zhang, X., & Gong, Z. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151535 · Cited by 14
Bai, H., Cheng, Y., Jia, S., Wang, X., Jin, R., Guo, H., Tang, Y., & Wang, Y. (2025) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-025-00624-1 · Cited by 13
“2-HG, a homologous metabolite with carcinogenic potential, inhibits α-KG-dependent enzymes involved in key biological processes, including epigenetic regulation, collagen synthesis and cell signaling [13].”
Zhu, Y., Chen, J., Kong, W., Mao, L., Kong, W., Zhou, Q., Zhou, Z., Zhu, B., Wang, Z., He, J., et al. (2017) · European Radiology · doi:10.1007/s00330-017-4957-y · Cited by 13
“IDH1/2 mutation was found in over 70% of diffuse or secondary glioma and 20% of acute myeloid leukaemia [6], approximately 50% of sporadic central and periosteal chondrosarcomas [7, 8], as well as in some other tumours [9].”
BackgroundMizuno, H., Koya, J., Masamoto, Y., Kagoya, Y., & Kurokawa, M. (2021) · Cancer Science · doi:10.1111/cas.15098 · Cited by 13
Tissue 2-Hydroxyglutarate and Preoperative Seizures in Patients With Diffuse Gliomas
Ohno, M., Hayashi, Y., Aikawa, H., Hayashi, M., Miyakita, Y., Takahashi, M., Matsushita, Y., Yoshida, A., Satomi, K., Ichimura, K., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012893 · Cited by 13
“Endogenous D2HG dehydrogenase limits the concentration of physiologic cellular D2HG; however, mutant IDH1/2 causes aberrant accumulation of D2HGwithin cells.(1) This high concentration of D2HG results in global histone and DNA methylation by inhibiting α-KG– dependent dioxygenases within tumor cells.”
BackgroundTargeting DNA repair in gliomas
Beckta, J. M., Bindra, R. S., & Chalmers, A. J. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000760 · Cited by 13
“IDH1 resides in both the cytosol and peroxisomes, whereas IDH2 localizes to mitochondria [59].”
BackgroundChurchill, H. R. O., Naina, H. V. K., Boriack, R. L., Rakheja, D., & Chen, W. (2015) · PubMed · Cited by 14
Metabolism: an important player in glioma survival and development
Wang, N., Yuan, Y., Hu, T., Xu, H., & Piao, H. (2024) · Discover Oncology · doi:10.1007/s12672-024-01402-5 · Cited by 17
Genetic analysis in the clinical management of biliary tract cancer
Wakai, T., Nagahashi, M., Shimada, Y., Prasoon, P., & Sakata, J. (2020) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12334 · Cited by 13
Lee, J. W., Uy, B. R., & Liau, L. M. (2021) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2021.01.003 · Cited by 12
A Brief Introduction to Current Cancer Gene Therapy
Kobelt, D., Pahle, J., & Walther, W. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2441-8_1 · Cited by 13
Heo, H., Kim, S., Lee, H. H., Cho, H. R., Xu, W. J., Lee, S., Park, C., Park, S., Choi, S. H., & Kim, H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147794 · Cited by 13
“The fluorescent microscopic images (Fig 1C) and the immunoblot analysis (Fig 1D) further confirmed the well–established F98 glioma cell lines for the IDH1/2–WT and IDH–R132H/–R172K expressions.”
BackgroundInfluentialYamamoto, M., Tanaka, H., Toki, Y., Hatayama, M., Ito, S., Addo, L., Shindo, M., Sasaki, K., Ikuta, K., Ohtake, T., et al. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2054-7 · Cited by 12
Tiburcio, P. D. B., Xiao, B., Berg, S., Asper, S., Lyne, S. B., Zhang, Y., Zhu, X., Yan, H., & Huang, L. E. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1800-0 · Cited by 12
Biomarker-Driven and Molecular Targeted Therapies for Hepatobiliary Cancers
Harris, W. P., Wong, K. M., Saha, S. K., Dika, I. E., & Abou‐Alfa, G. K. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.03.002 · Cited by 17
Sørensen, M. D., Nielsen, O., Reifenberger, G., & Kristensen, B. W. (2021) · Brain Pathology · doi:10.1111/bpa.12921 · Cited by 13
“…gliomas, d -2-hydroxyglutarate accumulates intra-and extracellularly up to concentrations that are 100-fold higher than in IDH-wildtype gliomas (5, 18, 19). d -2-hydroxyglutarate modifies the cellular energetics and epigenetics, including promotion of a DNA hypermethylation phenotype (5–7…”
InfluentialVoelxen, N., Walenta, S., Proescholdt, M. A., Dettmer, K., Pusch, S., & Mueller‐Klieser, W. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00046 · Cited by 14
Metabolic Enzymes in Sarcomagenesis: Progress Toward Biology and Therapy
Li, L., Eid, J. E., Paz, A. C., & Trent, J. C. (2017) · BioDrugs · doi:10.1007/s40259-017-0237-2 · Cited by 13
Enchondromatosis and Growth Plate Development
Zhang, H., & Alman, B. A. (2020) · Current Osteoporosis Reports · doi:10.1007/s11914-020-00639-7 · Cited by 14
Biostructural, biochemical and biophysical studies of mutant IDH1
McCoy, M. A., Lü, J., Miller, F. R., Soisson, S. M., Lam, M. H., & Fischer, C. (2024) · Nature Communications · doi:10.1038/s41467-024-51692-0 · Cited by 12
Xiao, K., Zhang, Z., Wu, Y., Li, G., Chen, J., Ren, Y., Yang, N., Zhou, J., Zhang, W., Wang, J., et al. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00625 · Cited by 13
Molecular prognostic factors in glioblastoma: state of the art and future challenges
Xavier‐Magalhães, A., Nandhabalan, M., Jones, C., & Costa, B. M. (2013) · CNS Oncology · doi:10.2217/cns.13.48 · Cited by 11
The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches
Gruber, E., & Kats, L. M. (2023) · Biochemical Society Transactions · doi:10.1042/bst20230017 · Cited by 11
Noncoding rules of survival: epigenetic regulation of normal and malignant hematopoiesis
Wallace, L. M., & Obeng, E. A. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1273046 · Cited by 12
Tong, H., Yu, X., Lu, X., & Wang, P. (2015) · IUBMB Life · doi:10.1002/iub.1372 · Cited by 11
“Oncometabolite-driven cancer metastasis mechanisms are taking important precedence in disease pathophysiology, including in glioblastoma in which altered glutamate levels are increasingly being identified as local metastatic signals (27).”
BackgroundFalini, B., & Martelli, M. P. (2015) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2015.10.005 · Cited by 11
“myelodysplastic syndromes and T-cell lymphoblastic leukemia (eg, DNMT3A mutations) [6] or solid tumors (eg, IDH1/2 mutations) [7].”
BackgroundCutting Edge Molecular Therapy for Acute Myeloid Leukemia
Miyamoto, K., & Minami, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145114 · Cited by 11
“Isocitrate dehydrogenases (IDH) are enzymes that catalyze the oxidative decarboxylation of isocitrate to a-ketoglutarate (α-KG) [38].”
BackgroundZhang, X., Kim, W. J., Rao, A. V., Jaman, E., Deibert, C. P., Sandlesh, P., Krueger, K., Allen, J. C., & Amankulor, N. M. (2022) · Neurosurgical FOCUS · doi:10.3171/2021.11.focus21489 · Cited by 11
Targeting TET2 as a Therapeutic Approach for Angioimmunoblastic T Cell Lymphoma
Hu, L., Zhang, X., Li, H., Lin, S., & Zang, S. (2022) · Cancers · doi:10.3390/cancers14225699 · Cited by 11
Isocitrate dehydrogenase mutations: new opportunities for translational research
Keum, Y., & Choi, B. Y. (2015) · BMB Reports · doi:10.5483/bmbrep.2015.48.5.021 · Cited by 11
“-KG as a cofactor, such as ten eleven translocases (TETs), JmjC histone demethylases, and prolyl-hydroxylases (18).”
BackgroundEffects of deranged metabolism on epigenetic changes in cancer
Chandra, V., & Hong, K. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0561-3 · Cited by 12
Chen, X., Li, Q., Wang, C., Xu, W., Han, L., Liu, Y., Liu, B., Guan, S., Tan, B., Wang, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13351 · Cited by 11
“IDH1 plays driving roles in the metabolism of glucose, fatty acids, and glutamine as well as the maintenance of cellular redox status; IDH1 is located in the cytoplasm and peroxisomes [19].”
BackgroundIdentification of Isocitrate Dehydrogenase 2 (IDH2) Mutation in Carotid Body Paraganglioma
Lang, F., Jha, A., Meuter, L., Pacák, K., & Yang, C. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.731096 · Cited by 11
Weber, V., Arnaud, L., Dukić-Stefanović, S., Wenzel, B., Roux, V., Chezal, J., Lai, T. H., Teodoro, R., Kopka, K., Miot-Noirault, É., et al. (2022) · Molecules · doi:10.3390/molecules27123766 · Cited by 10
“These mutations induce a neomorphic activity, namely, conversion of α-KG to D-2-hydroxyglutarate (D2HG), which has been identified as an important oncometabolite involved in different signalling pathways, such as cell proliferation and apoptosis, but also in inducing DNA and histone methylation changes, thus promoting…”
BackgroundShayanfar, N., Zare‐Mirzaie, A., Mohammadpour, M., Jafari, E., Mehrtash, A., Emtiazi, N., & Tajik, F. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04336-z · Cited by 10
“IDH1 mutations are heterogenous missense mutations restricted to a single arginine residue, R132, in the active region of the enzyme (Cairns and Mak 2013).”
BackgroundThamim, M., Agrahari, A. K., Gupta, P. K., & Thirumoorthy, K. (2023) · Molecules · doi:10.3390/molecules28052315 · Cited by 10
“Introduction The wild-type cytosolic and mitochondrial homodimeric isocitrate dehydrogenase (IDH1/2) enzymes often catalyze the reversible oxidative decarboxylation of isocitrate into αketoglutarate (α-KG) using nicotinamide adenine dinucleotide phosphate (NADP+/NADPH) as a cofactor [1].”
MethodStructure-based discovery of IHMT-IDH1-053 as a potent irreversible IDH1 mutant selective inhibitor
Liang, Q., Wang, B., Zou, F., Guo, G., Wang, W., Wang, W., Liu, Q., Shen, L., Hu, C., Wang, W., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115411 · Cited by 10
A Förster resonance energy transfer-based d-2-hydroxyglutarate biosensor
Xiao, D., Xu, X., Gao, K., Wang, M., Zhang, W., Lü, C., Wang, X., Wang, Q., Xu, P., Ma, C., et al. (2023) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2023.133681 · Cited by 10
Urbanovská, I., Houdova, M. M., Dwight, Z., Kalita, O., Uvírová, M., Šímová, J., Tučková, L., Buzrla, P., Palecek, T., Hajdúch, M., et al. (2018) · Pathology & Oncology Research · doi:10.1007/s12253-018-0413-9 · Cited by 10
“[7], reprograms metabolism [8], affects DNA methylation [9, 10], and may be followed by IDH change from tumour driver to passenger [11].”
Background
Metadata
- Authors
- Cairns, R. A., & Mak, T. W.
- Affiliations
- University Health Network (CA)
- Venue
- Cancer Discovery
- Published
- 2013-07-01
- Volume
- 3
- Issue
- 7
- Pages
- 730-741
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2111163869
- Cited by
- 452
- References
- 77
- Citations by year
- 2026: 16 · 2025: 18 · 2024: 26 · 2023: 26 · 2022: 31 · 2021: 33 · 2020: 45 · 2019: 33 · 2018: 43 · 2017: 46 · 2016: 50 · 2015: 44 · 2014: 37 · 2013: 4
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Association for Cancer Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- IDH mutation, IDH1, IDH2, 2-hydroxyglutarate, oncometabolites, alpha-ketoglutarate, gain-of-function mutations, epigenetic regulation, collagen synthesis, knock-in mice, glioma, acute myeloid leukemia, cholangiocarcinoma, angioimmunoblastic T-cell lymphoma, chondrosarcoma, carcinogenesis
- MeSH terms
- Animals, Arginine, Glutarates, Humans, Isocitrate Dehydrogenase, Mutation, Neoplasms, Gene Expression Regulation, Neoplastic, Epigenesis, Genetic, Mice, Gene Knock-In Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.